The Journal of Headache and Pain | |
Rizatriptan in migraineurs with unilateral cranial autonomic symptoms: a double-blind trial | |
Clinical Trials | |
Gabriella Egeo1  Luisa Fofi1  Cinzia Aurilia1  Piero Barbanti1  Nicola Vanacore2  Valentina Dall’Armi3  Stefano Bonassi3  | |
[1] Headache and Pain Unit, Department of Neurological, Motor and Sensorial Sciences, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy;National Center of Epidemiology, National Institute of Health, Rome, Italy;Unit of Clinical and Molecular Epidemiology, IRCCS San Raffaele Pisana, Via della Pisana 235, 00163, Rome, Italy; | |
关键词: Migraine; Cranial autonomic symptoms; Trigemino-autonomic reflex; Treatment; Rizatriptan; | |
DOI : 10.1007/s10194-012-0440-y | |
received in 2012-02-03, accepted in 2012-03-12, 发布年份 2012 | |
来源: Springer | |
【 摘 要 】
The objective and background is to confirm in a double-blind, placebo-controlled study the high triptan response rates we had previously reported in an open study in migraine patients with unilateral cranial autonomic symptoms. In this randomized, double-blind, placebo-controlled study 80 migraineurs with unilateral cranial autonomic symptoms were assigned to receive rizatriptan 10 mg wafer or placebo (ratio 1:1) and treated for a single moderate or severe migraine attack. The primary endpoints were pain freedom at 2 h and total migraine freedom at 2 h. Secondary endpoints included pain relief, no associated symptoms and sustained pain freedom or relief. Significantly more patients reported pain freedom at 2 h after taking rizatriptan (54 %) than after placebo (8 %) (therapeutic gain 46 % [28 %; 64 %]; P < 0.001). Similarly, significantly more patients reported total migraine freedom at 2 h after rizatriptan (51 %) than after placebo (8 %) (therapeutic gain 43 % [26 %; 61 %]; P < 0.001). Rizatriptan was also more effective than placebo on most secondary endpoints. We confirm in a placebo-controlled study our previous data suggesting that the presence of unilateral cranial autonomic symptoms in migraineurs predicts a positive response to triptans, probably owing to intense trigeminal peripheral afferent activation which strongly recruits peripheral neurovascular 5-HT1B/1D receptors. Acute and preventive pharmacological trials in migraine should focus also on this subset of migraine patients.
【 授权许可】
CC BY
© The Author(s) 2012
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202310134656559ZK.pdf | 181KB | download |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]